Clinically, there is no Anlatinib, it should be Anrotinib, which is a multi-target tyrosine kinase inhibitor with angiogenesis inhibition and anti-tumor effects, and can be used for eligible patients with lung cancer, soft tissue sarcoma, and thyroid cancer.
Anrotinib is a domestically produced targeted drug that can antagonize multiple targets such as vascular endothelial growth factor to inhibit angiogenesis and anti-tumor effects, and has been approved for use in patients with a variety of malignant tumors.
Currently, the approved indications for Anrotinib include advanced or metastatic non-small cell lung cancer that has progressed after receiving two or more prior chemotherapy regimens; soft tissue sarcoma that has progressed or relapsed after receiving a prior anthracycline-based chemotherapy regimen; and advanced or metastatic medullary thyroid carcinoma that is definitively progressed and is not amenable to surgical resection.
Common adverse reactions to amlotinib include hypertension, fatigue, hand-foot syndrome, hyperlipidemia, and hypothyroidism. It should be contraindicated in patients who are allergic to drug components, at risk of hemoptysis, pregnant and lactating women, and those with severe hepatic or renal insufficiency.
The use of Anrotinib has strict indications and contraindications, so it is not recommended to use it on your own, it is recommended to consult a professional doctor to fully assess the condition and decide whether to use it.